The Long-term (10.6 years) Outcome of Hepatitis C patients with Sustained Virologic Response Following Treatment with Pegylated Interferon + Ribavirin
Journal Title: Viral Hepatitis Journal - Year 2020, Vol 26, Issue 1
Abstract
Objectives: Directly-acting anti-viral agents for the treatment of hepatitis C have been revolutionised. In the meantime, hepatitis C patients with sustained virologic response (SVR) achieved with previous treatments have been forgotten. Hepatitis C patients with SVR achived by pegylated interferon + ribavirin (INF + RIB) treatment are followed and it is investigated whether cirrhosis, hepatocellular carcinoma (HCC) and/or decompensation developed or not in these patients. Materials and Methods: One hundred thirty-five patients with hepatitis C virus who achieved SVR with pegylated INF alpha + RIB treatment between 2006 and 2010 are included in the study. At least twice a year, these patients were followed-up with ultrasonography, alpha fetoprotein and routine laboratory tests. Results: Out of the patients, 97.8% were genotype 1 and 95% were evaluated with biopsy before the treatment. One hundred twenty non-cirrhotic patients and 15 patients with compensated cirrhosis were followed for a period of 10.6 years (distribution: 9-13 years). None of the non-cirrhotic patients developed cirrhosis or HCC. HCC was developed in one of 15 cirrhotic patients (6 years after the treatment), resulting in the death of the patient. There were no decompensation case. Conclusion: It is evaluated that non-cirrhotic hepatitis C patients who achieved SVR with pegylated INF can be followed in a wider range of time. There should be a strict follow-up of cirrhotic patients, especially for HCC development.
Authors and Affiliations
Osman Özdoğan, Serkan Yaraş
Keywords
Related Articles
- EP ID EP684576
- DOI 10.4274/vhd.galenos.2019.2019.0042
- Views 145
- Downloads 0
The Impact of COVID-19 Pandemic on Treatment, Follow-up and Behavioral Characteristics of Chronic Viral Hepatitis Patients
Objectives: It has been not yet fully understood whether chronic liver diseases may be considered as risk factors for critical course of Coronavirus disease-2019 (COVID-19). Considering the importance of managing with CO...
Evaluation of Hepatitis A Seroprevalance and Epidemiologic Data of Patients Applying to A Medical Faculty Hospital
Objectives: Our study aims to determine seroprevalence of hepatitis A virus (HAV) in our region and to determine the prevalence change over years and to evaluate the effects of various factors on prevalence. Materials a...
Consideration Whether Hepatitis B Exists in Children Whose Mothers Suffer from Chronic Hepatitis B and These Mothers in Gestational Age
Objectives: Perinatal and intrauterine transmission of the hepatitis B virus (HBV) represents a major factor, leading to the development of chronic infection. This study aimed to explore the status of mothers and their c...
Hepatitis B Virus Infection: Knowledge and Awareness Among the Patients Admitted in a Tertiary Care Hospital in Bangladesh
Objectives: Hepatitis B virus (HBV) infection is a major cause of morbidity and mortality in Bangladesh. An adequate level of knowledge and awareness among the general population is essential in prevention and control of...
Seroprevalence Investigation of Hepatitis B and Hepatitis B Core Antigen in Oncology Patients
Objectives: Hepatitis B virus (HBV) affects a significant part of society and is characterized by high mortality and morbidity. Hepatitis B affects approximately 350 million people worldwide, many of whom are chronic pat...